Literature DB >> 1431352

[Biochemical analysis of lipopolysaccharides from respiratory pathogenic Branhamella catarrhalis strains and the role of anti-LPS antibodies in Branhamella respiratory infections].

H Tanaka1, K Oishi, F Sonoda, A Iwagaki, T Nagatake, K Matsumoto.   

Abstract

We characterized lipopolysaccharides (LPSs) from respiratory pathogenic Branhamella catarrhalis (BC) strains, and evaluated the protective property of anti-BC LPS antibody in BC respiratory infections. LPSs from four strains of BC were lipooligosaccharide having no O-side chain and a M(r) of 3 KDa, as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). All of them produced different patterns, showing two to four bands on SDS-PAGE. We found high level of anti-BC IgG antibody in convalescent sera from a patient with BC respiratory tract infection by ELISA. This IgG antibody recognized BC LPSs on Western blots. Two respiratory pathogens of BC (strains; 87-122, 88-23) were tested in a bactericidal assay employing a convalescent sera. 87-122 strain was susceptible to antibody-dependent, complement-mediated killing, while 88-23 strain was resistant. The killing of 87-122 strain was inhibited by addition of the homologous BC LPS to the convalescent sera in a dose-dependent manner. These data support that anti-BC LPS antibody may mediate complement-lysis of some strains of BC, and play a protective role in BC respiratory infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431352     DOI: 10.11150/kansenshogakuzasshi1970.66.709

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  8 in total

1.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

3.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.

Authors:  Xinan Jiao; Takashi Hirano; Yingchun Hou; Xin-Xing Gu
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides.

Authors:  K Oishi; H Tanaka; F Sonoda; S Borann; K Ahmed; Y Utsunomiya; K Watanabe; T Nagatake; M Vaneechoutte; G Verschraegen; K Matsumoto
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.

Authors:  W G Hu; J Chen; J F Battey; X X Gu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

7.  Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis.

Authors:  W G Hu; J Chen; J C McMichael; X X Gu
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.

Authors:  Shengqing Yu; Hang Xie; Anup Datta; Natasha Naidu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.